Preliminary Safety and Efficacy of Navitoclax Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis From the Multicenter, Open-Label, Phase 2 Study (REFINE) - PubMed
2 months ago
- #clinical trial
- #BCL-2 inhibitor
- #myelofibrosis
- 研究评估navitoclax联合ruxolitinib在未接受过JAK抑制剂治疗的骨髓纤维化患者中的疗效
- 主要终点：63%患者在24周时实现≥35%脾脏体积缩小(SVR35)
- 次要结果：41%达到≥50%症状评分改善(TSS50)；48%显示骨髓纤维化程度改善
- 贫血缓解率：非输血依赖患者38%，输血依赖患者达100%
- 安全性良好，未出现与navitoclax相关的出血事件或死亡病例